0000899243-15-009749.txt : 20151211
0000899243-15-009749.hdr.sgml : 20151211
20151211210032
ACCESSION NUMBER: 0000899243-15-009749
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151210
FILED AS OF DATE: 20151211
DATE AS OF CHANGE: 20151211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2066960703
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harr Steve
CENTRAL INDEX KEY: 0001627387
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 151284438
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE. 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-12-10
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001627387
Harr Steve
307 WESTLAKE AVENUE NORTH, SUITE 300
SEATTLE
WA
98109
0
1
0
0
See Remarks
Common Stock
2015-12-10
4
S
0
31400
46.3774
D
768600
D
Common Stock
2015-12-10
4
S
0
3600
46.8955
D
765000
D
This transaction was executed in multiple trades at prices ranging from $45.82 to $46.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $46.82 to $47.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015.
Chief Financial Officer and Head of Corporate Development
/s/ Zachary Hale, attorney-in-fact
2015-12-11